– Elhan WebbCFA, formerly of Rubius Therapeutics and Radius Health, named senior vice president of Investor Relationship –
– Webb brings over 20 years of diverse international experience in investor relations, business development, investment analysis and portfolio management in healthcare and biotechnology –
NEWTON, Mass., March 14, 2022 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Elhan Webb as Senior Vice President of Investor Relations.
“Elhan brings to Karyopharm considerable experience with sell-side and buy-side analysts, as well as a strong network of the financial community and biotech investments,” said Richard Paulson, Chairman and CEO of Karyopharm. “Elhan has a proven track record of building top-notch investor relations functions, and she will leverage this expertise to build awareness and understanding of Karyopharm’s strong portfolio, pipeline and vision for the future. We are excited to have him on the team.”
Ms. Webb brings over 20 years of experience to her new role. Most recently, she served as Vice President of Investor Relations at Rubius Therapeutics. Previously, she was Head of Investor Relations at Radius Health and Genfit. While at Roche Investor Relations, Ms. Webb led investor relations activities for Roche Diagnostics. She has also held business development positions at Roche Molecular Diagnostics and Morphochem. Earlier in her career, Ms. Webb spent more than a decade in Europe manage and direct healthcare investments in financial institutions such as BB Biotech-Bellevue Asset Management, Cantrade-UBS and Lombard Odier.
Ms. Webb holds a Masters of Business Administration from the University of Southern California and an undergraduate degree in economics Bogazici University in Istanbul, Turkey. She is also a CFA charter holder.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its inception, Karyopharm has been the industry leader in oral Selective Nuclear Export Inhibitor (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: the dysregulation of nuclear export. . XPOVIO® (selinexor), Karyopharm’s lead SINE compound and its first oral exportin 1 (XPO1) inhibitor, is approved in the United States and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a number of former U.S. territories and countries, including Europe and the UK (like NEXPOVIO®), China and Singapore. Karyopharm has a focused pipeline targeting several high unmet need cancer indications including endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, the science and the pipeline, please visit www.karyopharm.comand follow us on Twitter at @Karyopharm and LinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include those regarding the ability of selinexor or eltanexor to treat patients with multiple myeloma, diffuse large cell lymphoma B, tumors and other diseases; and expectations related to future clinical development and potential regulatory submissions of selinexor or eltanexor. These statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm’s control, which may cause actual events or results to differ materially from Karyopharm’s current expectations. For example, there can be no assurance that Karyopharm will be successful in obtaining regulatory approval for selinexor as first-line maintenance therapy after chemotherapy in patients with advanced or recurrent endometrial cancer; that Karyopharm will successfully commercialize XPOVIO; that regulators will grant confirmatory approval in the European Union based on the BOSTON study in adult patients with multiple myeloma; or that any of Karyopharm’s drug candidates, including selinexor and eltanexor, will successfully complete the necessary phases of clinical development or that development of any of Karyopharm’s drug candidates will continue. In addition, there can be no assurance that any positive development in the development or commercialization of Karyopharm’s pipeline of drug candidates will result in stock price appreciation. Management’s expectations and, accordingly, any forward-looking statements contained in this press release may also be affected by risks and uncertainties relating to a number of other factors, including the following: the risk that the COVID-19 pandemic 19 could disrupt Karyopharm’s business more severely than it currently anticipates, including negatively impacting XPOVIO’s sales, interrupting or delaying research and development efforts, affecting the ability to secure sufficient supply for the development and commercialization of selinexor or other product candidates, delaying ongoing or planned clinical trials, impeding the execution of business plans, anticipated regulatory milestones and timelines, or inconveniencing patients; commercial market adoption of XPOVIO, the timing and costs involved in commercializing XPOVIO or any Karyopharm drug candidate that receives regulatory approval; the ability to obtain and maintain regulatory approval for XPOVIO or any Karyopharm drug candidate that receives regulatory approval; results of Karyopharm’s clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, clinical trial site research review boards, and publication review bodies, including regarding the need for additional clinical studies; the ability of Karyopharm or its third party collaborators or assigns to fully perform their respective obligations under the applicable agreement and any future financial implications of such agreement; Karyopharm’s ability to enroll patients in its clinical trials; unforeseen cash requirements and expenditures; the development or regulatory approval of drug candidates by Karyopharm’s competitors for products or product candidates in which Karyopharm currently markets or develops; and Karyopharm’s ability to obtain, maintain and enforce patent and other intellectual property protections for any of its products or product candidates. These and other risks are described under “Risk Factors” in Karyopharm’s Quarterly Report on Form 10-K for the year ended. December 31, 2021which was filed with the Securities and Exchange Commission (SEC) on March 1, 2022, and in other filings that Karyopharm may file with the SEC in the future. All forward-looking statements contained in this press release speak only as of the date hereof and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. All other trademarks mentioned herein are the property of their respective owners.
SOURCE Karyopharm Therapeutics Inc.